Kodiak Sciences

Kodiak Sciences

Biotechnology
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.

$6.4B

Market Cap • 11/20/2026

2009

(17 years)

Founded

2018

(8 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

505,4

P/S

—

P/EBITDA

—

P/OCF

—

P/FCF

—

P/E

—

BVPS

0,2

EPS

—

Market Cap

Market Cap

6,4B

EV

6,3B

EV/Revenue

—

EV/EBITDA

-27,8

EV/EBIT

-25,1

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-3%

Total Yield

-3%

Payout

0%

Retained Earnings

-1,7B

Profitability

Gross Margin

—

EBITDA Margin

—

EBIT Margin

—

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

0%

Capex/Revenue

0%

Capex/D&A

13,9%

Capex/OCF

-2%

SBC/OCF

—

% PPE

49,5%

% Goodwill

0%

ROE

—

ROIC

—

Growth

CAGR Op. Income 5Y

2,6%

CAGR Net Income 5Y

2,3%

CAGR EPS 5Y

-1,2%

CAGR OCF 5Y

2,4%

Leverage

N.D./EBITDA

0,2

Debt/Equity

0%

Current Ratio

1,7

Quick Ratio

1,6

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium